Dose-volume relationship for laryngeal substructures and aspiration in patients with locally advanced head-and-neck cancer.
Adult
Aged
Carcinoma, Squamous Cell
/ pathology
Chemoradiotherapy
/ adverse effects
Deglutition Disorders
/ etiology
Female
Head and Neck Neoplasms
/ pathology
Humans
Larynx
/ pathology
Male
Middle Aged
Prognosis
Prospective Studies
Radiotherapy Dosage
Radiotherapy, Intensity-Modulated
/ adverse effects
Aspiration
Head-and-neck cancer
Larynx
Radiotherapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
18 Mar 2019
18 Mar 2019
Historique:
received:
30
10
2018
accepted:
01
03
2019
entrez:
20
3
2019
pubmed:
20
3
2019
medline:
29
5
2019
Statut:
epublish
Résumé
Literature has shown a significant relationship between radiation dose to the larynx and swallowing disorders. We prospectively studied the dose-volume relationship for larynx substructures and aspiration. Forty nine patients with stage III/IV head-and-neck (H&N) squamous cell carcinoma were prospectively enrolled in this IRB-approved, federally funded study. All patients received IMRT-based chemoradiation therapy (CRT) and were scheduled for videofluorography (VFG) prior to CRT and at 3, 6, 9, 12, and 24 months post-CRT. Twelve laryngeal substructures were contoured in each patient: thyroid cartilage, cricoid cartilage, total epiglottis, suprahyoid epiglottis, infrahyoid epiglottis, total larynx, supraglottic larynx, subglottic larynx, glottic larynx, arytenoids, aryepiglottic (AE) folds, and glossoepiglottic fold. After exclusions, 29 patients were included in the final analysis. Incidence of aspiration at 1 year following CRT was correlated with dose-volume data to laryngeal substructures using logistic regression. The median age was 54 years with 79% being non-smokers. Tumor sites included oropharynx (22), unknown primary (6), and hypopharynx (1). One year following CRT, 10/29 (34%) showed aspiration on VFG. Dose to the AE folds showed the highest correlation with aspiration at 12 months and was significant on multivariate analysis (p = 0.025). A mean dose cutpoint of 6500 cGy or higher to the AE folds was associated with an increased risk of aspiration at 1 year [positive likelihood ratio (+LR) 2.81, positive predictive value (PPV) 60%, negative predictive value (NPV) 92.9%, relative risk (RR) 8.4]. In this analysis, mean dose to the AE folds was associated with an increased risk of aspiration at 1 year. However, these are hypothesis-generating data that require further research and validation in a larger patient subset.
Sections du résumé
BACKGROUND
BACKGROUND
Literature has shown a significant relationship between radiation dose to the larynx and swallowing disorders. We prospectively studied the dose-volume relationship for larynx substructures and aspiration.
METHODS
METHODS
Forty nine patients with stage III/IV head-and-neck (H&N) squamous cell carcinoma were prospectively enrolled in this IRB-approved, federally funded study. All patients received IMRT-based chemoradiation therapy (CRT) and were scheduled for videofluorography (VFG) prior to CRT and at 3, 6, 9, 12, and 24 months post-CRT. Twelve laryngeal substructures were contoured in each patient: thyroid cartilage, cricoid cartilage, total epiglottis, suprahyoid epiglottis, infrahyoid epiglottis, total larynx, supraglottic larynx, subglottic larynx, glottic larynx, arytenoids, aryepiglottic (AE) folds, and glossoepiglottic fold. After exclusions, 29 patients were included in the final analysis. Incidence of aspiration at 1 year following CRT was correlated with dose-volume data to laryngeal substructures using logistic regression.
RESULTS
RESULTS
The median age was 54 years with 79% being non-smokers. Tumor sites included oropharynx (22), unknown primary (6), and hypopharynx (1). One year following CRT, 10/29 (34%) showed aspiration on VFG. Dose to the AE folds showed the highest correlation with aspiration at 12 months and was significant on multivariate analysis (p = 0.025). A mean dose cutpoint of 6500 cGy or higher to the AE folds was associated with an increased risk of aspiration at 1 year [positive likelihood ratio (+LR) 2.81, positive predictive value (PPV) 60%, negative predictive value (NPV) 92.9%, relative risk (RR) 8.4].
CONCLUSIONS
CONCLUSIONS
In this analysis, mean dose to the AE folds was associated with an increased risk of aspiration at 1 year. However, these are hypothesis-generating data that require further research and validation in a larger patient subset.
Identifiants
pubmed: 30885235
doi: 10.1186/s13014-019-1247-7
pii: 10.1186/s13014-019-1247-7
pmc: PMC6423881
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
49Subventions
Organisme : NIDCD NIH HHS
ID : R01 DC007659
Pays : United States
Organisme : National Institutes of Health
ID : R01 DC007659
Références
J Clin Oncol. 1999 Mar;17(3):1020-8
pubmed: 10071297
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):577-87
pubmed: 10524409
Int J Cancer. 2000 Apr 20;90(2):92-103
pubmed: 10814959
Int J Cancer. 2001;96 Suppl:61-70
pubmed: 11992387
Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8
pubmed: 12007937
Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39
pubmed: 15590174
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):772-8
pubmed: 15708256
Otolaryngol Head Neck Surg. 2006 Jun;134(6):916-22
pubmed: 16730530
Int J Radiat Oncol Biol Phys. 1992;22(1):3-11
pubmed: 1727126
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):750-7
pubmed: 17418971
Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1289-98
pubmed: 17560051
Radiother Oncol. 2007 Oct;85(1):74-82
pubmed: 17673322
Head Neck. 2008 Feb;30(2):148-58
pubmed: 17786992
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1110-8
pubmed: 18468812
Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1088-95
pubmed: 18707823
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):403-9
pubmed: 19467801
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):385-92
pubmed: 19553033
Radiother Oncol. 2012 Oct;105(1):107-14
pubmed: 21907437
Ann Rehabil Med. 2011 Dec;35(6):781-90
pubmed: 22506206
Radiother Oncol. 2013 Jun;107(3):288-94
pubmed: 23791365
Am J Clin Oncol. 2015 Dec;38(6):588-94
pubmed: 24136140
Oral Oncol. 2014 Jan;50(1):65-70
pubmed: 24238851
Head Neck. 2016 Apr;38(4):517-21
pubmed: 25351675
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1165-1174
pubmed: 26194685
Radiother Oncol. 2015 Oct;117(1):83-90
pubmed: 26277855
BMC Cancer. 2016 Oct 6;16(1):770
pubmed: 27716125
Oral Oncol. 2017 Jan;64:9-14
pubmed: 28024728
Radiother Oncol. 2019 Jan;130:62-67
pubmed: 30420235
Int J Radiat Oncol Biol Phys. 1983 Mar;9(3):321-8
pubmed: 6841183
Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):577-88
pubmed: 7790242
Oncology (Williston Park). 1997 May;11(5):651-6, 659; discussion 659, 663-4
pubmed: 9159792
Clin Oncol (R Coll Radiol). 1997;9(5):308-12
pubmed: 9368726